1. Hubeau, Céline, Rocks, Natacha, Cataldo, Didier. 2020. ADAM28: Another ambivalent protease in cancer. In Cancer letters, 494, 18-26. doi:10.1016/j.canlet.2020.08.031. https://pubmed.ncbi.nlm.nih.gov/32861707/
2. Mochizuki, Satsuki, Okada, Yasunori. . ADAM28 as a target for human cancers. In Current pharmaceutical design, 15, 2349-58. doi:. https://pubmed.ncbi.nlm.nih.gov/19601836/
3. Sasaki, Aya, Abe, Hitoshi, Mochizuki, Satsuki, Shimoda, Masayuki, Okada, Yasunori. 2018. SOX4, an epithelial-mesenchymal transition inducer, transactivates ADAM28 gene expression and co-localizes with ADAM28 at the invasive front of human breast and lung carcinomas. In Pathology international, , . doi:10.1111/pin.12685. https://pubmed.ncbi.nlm.nih.gov/29882245/
4. Miyamae, Yuka, Mochizuki, Satsuki, Shimoda, Masayuki, Kitagawa, Yuko, Okada, Yasunori. 2016. ADAM28 is expressed by epithelial cells in human normal tissues and protects from C1q-induced cell death. In The FEBS journal, 283, 1574-94. doi:10.1111/febs.13693. https://pubmed.ncbi.nlm.nih.gov/26918856/
5. Wei, Li, Wen, Jing-Yun, Chen, Jie, Chen, Zhan-Hong, Huang, Jiang-Long. . Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer. In World journal of gastroenterology, 25, 5590-5603. doi:10.3748/wjg.v25.i37.5590. https://pubmed.ncbi.nlm.nih.gov/31602160/
6. Mochizuki, Satsuki, Soejima, Kenji, Shimoda, Masayuki, Okano, Hideyuki, Okada, Yasunori. 2012. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. In Journal of the National Cancer Institute, 104, 906-22. doi:10.1093/jnci/djs232. https://pubmed.ncbi.nlm.nih.gov/22636800/
7. Yin, Qianru, Gu, Jiayi, Qi, Yingxue, Liu, Jianwen, Liang, Xin. 2021. ADAM28 from both endothelium and gastric cancer cleaves von Willebrand Factor to eliminate von Willebrand Factor-induced apoptosis of gastric cancer cells. In European journal of pharmacology, 898, 173994. doi:10.1016/j.ejphar.2021.173994. https://pubmed.ncbi.nlm.nih.gov/33675784/
智鼠故事 
